274 related articles for article (PubMed ID: 24407240)
21. An important role for CDK2 in G1 to S checkpoint activation and DNA damage response in human embryonic stem cells.
Neganova I; Vilella F; Atkinson SP; Lloret M; Passos JF; von Zglinicki T; O'Connor JE; Burks D; Jones R; Armstrong L; Lako M
Stem Cells; 2011 Apr; 29(4):651-9. PubMed ID: 21319273
[TBL] [Abstract][Full Text] [Related]
22. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
23. Dual regulation of the anaphase promoting complex in human cells by cyclin A-Cdk2 and cyclin A-Cdk1 complexes.
Mitra J; Enders GH; Azizkhan-Clifford J; Lengel KL
Cell Cycle; 2006 Mar; 5(6):661-6. PubMed ID: 16582612
[TBL] [Abstract][Full Text] [Related]
24. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
[TBL] [Abstract][Full Text] [Related]
25. ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability.
Goetz EM; Shankar B; Zou Y; Morales JC; Luo X; Araki S; Bachoo R; Mayo LD; Boothman DA
Oncogene; 2011 Sep; 30(35):3745-54. PubMed ID: 21460853
[TBL] [Abstract][Full Text] [Related]
26. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
27. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation.
Ando K; Ozaki T; Yamamoto H; Furuya K; Hosoda M; Hayashi S; Fukuzawa M; Nakagawara A
J Biol Chem; 2004 Jun; 279(24):25549-61. PubMed ID: 15024021
[TBL] [Abstract][Full Text] [Related]
28. The p53-p21WAF1 checkpoint pathway plays a protective role in preventing DNA rereplication induced by abrogation of FOXF1 function.
Lo PK; Lee JS; Sukumar S
Cell Signal; 2012 Jan; 24(1):316-24. PubMed ID: 21964066
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of Polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway.
Kim HJ; Cho JH; Kim JR
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1145-56. PubMed ID: 23525475
[TBL] [Abstract][Full Text] [Related]
30. Normal cells, but not cancer cells, survive severe Plk1 depletion.
Liu X; Lei M; Erikson RL
Mol Cell Biol; 2006 Mar; 26(6):2093-108. PubMed ID: 16507989
[TBL] [Abstract][Full Text] [Related]
31. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
32. FRET-Based Sorting of Live Cells Reveals Shifted Balance between PLK1 and CDK1 Activities During Checkpoint Recovery.
Lafranchi L; Müllers E; Rutishauser D; Lindqvist A
Cells; 2020 Sep; 9(9):. PubMed ID: 32961751
[TBL] [Abstract][Full Text] [Related]
33. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
34. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.
Xie S; Wu H; Wang Q; Cogswell JP; Husain I; Conn C; Stambrook P; Jhanwar-Uniyal M; Dai W
J Biol Chem; 2001 Nov; 276(46):43305-12. PubMed ID: 11551930
[TBL] [Abstract][Full Text] [Related]
35. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
36. Plk1, a negative regulator of p21?
Liu X
Cell Cycle; 2009 Feb; 8(3):336-7. PubMed ID: 19164953
[No Abstract] [Full Text] [Related]
37. Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage.
Tsvetkov L; Stern DF
Cell Cycle; 2005 Jan; 4(1):166-71. PubMed ID: 15611664
[TBL] [Abstract][Full Text] [Related]
38. Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein α to mediate colon carcinoma cell differentiation and apoptosis.
Dasgupta N; Thakur BK; Ta A; Das S; Banik G; Das S
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1777-1787. PubMed ID: 28341486
[TBL] [Abstract][Full Text] [Related]
39. The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation.
Smith L; Farzan R; Ali S; Buluwela L; Saurin AT; Meek DW
Sci Rep; 2017 Nov; 7(1):16115. PubMed ID: 29170437
[TBL] [Abstract][Full Text] [Related]
40. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest.
Manni I; Mazzaro G; Gurtner A; Mantovani R; Haugwitz U; Krause K; Engeland K; Sacchi A; Soddu S; Piaggio G
J Biol Chem; 2001 Feb; 276(8):5570-6. PubMed ID: 11096075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
